ROZLYTREK (entrectinib) capsules is used for the treatment of patients with non-small cell lung cancer Treatment

ROZLYTREK is a kinase inhibitor indicated for the treatment of: • Adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. (1.1) • Adult and pediatric patients 12 years of age and older with solid tumors

Rozlytrek (entrectinib) capsules suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of Rozlytrek (entrectinib) capsules brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the Rozlytrek (entrectinib) capsules tablets cost price in India.

The order for Rozlytrek (entrectinib) capsules will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Entrectinib (INN, trade name Rozlytrek previously known as RXDX-101 and NMS-E628) is an anti-cancer drug used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It was approved in the United States on 15 August 2019. It is a selective tyrosine kinase inhibitor (TKI), of the tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK).

Rozlytrek (entrectinib) capsules tablets, for oral use. Initial U.S. Approval: 2017

Generic Name: Entrectinib

ROZLYTREK (entrectinib) capsules Price In Delhi India.

Get In Touch

Indian Pharma Network (IPN), Delhi. India

IPN, Delhi is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India. IPN, New Delhi helps patient, providing solutions on how to get access of anti cancer medicines which is not available in India.

BRANCH OFFICE : NEW DELHI | BENGALURU | KOLKATA | LUCKNOW | JODHPUR

Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Saudi Arabia | South Africa

Indian Pharma Network

60/4 1st Floor, T&T Building, Indian Oil Complex,
Yusuf Sarai, New Delhi, Delhi 110016

Mobile / WhatsApp / Phone

M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398

Free Customer Support

info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in

Rozlytrek (entrectinib) capsules suppliers in India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Rozlytrek (entrectinib) capsules on prescription and Import License in Patient's Name only.

For overseas patients, Rozlytrek (entrectinib) capsules can be made available in Send your enquiry to find Rozlytrek (entrectinib) capsules in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

News / Update for Rozlytrek (entrectinib) capsules.

For Rozlytrek (entrectinib) capsules Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours For More Details

FDA Approves Entrectinib for ROS1+ NSCLC and NTRK+ Solid Tumors